Bristol-Myers Squibb Stock Is Too Cheap to Ignore

Bristol-Myers Squibb Stock Is Too Cheap to Ignore

Also, the U.S. Federal Trade Commission (FTC) expressed antitrust concerns after the acquisition was announced. Bristol-Myers sold Celgene’s psoriasis drug Otezla to Amgen (NASDAQ:AMGN) for $13.4 …